This report provides an overview of the AML and blood cancer diagnostics market. Most tests commonly performed on patients with an AML diagnosis (or suspected diagnosis) are standard hematopathogical tests probing cancer cell histology and cytogenetics, but techniques that probe the molecular-mutational landscape of AML have become commonplace as well. At present, most of these tests have prognostic value but may not change treatment options for the majority of patients, given the lack of targeted treatment options available in AML. This perspective is rapidly evolving with targeted therapies that could hit the AML market in the near future.

This report was written in collaboration with MedDeviceTracker. For more information on MedDeviceTracker's diagnostics coverage, please visit the MedDeviceTracker website or contact your BioMedTracker sales representative.

This report accompanies our other AML content released in April 2015. We also published an interview with a KOL (pediatric AML/ALL specialist), an interview with an MDS/AML specialist, and a report on AML drug pipelines.

For the full report, please download the PDF version at the top of this page. For our disclosures, please read the BioMedTracker Research Standards.